Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Azienda Ospedaliera Universitaria Senese
Sponsor:
Collaborator:
MedImmune LLC
Information provided by (Responsible Party):
Michele Maio, Azienda Ospedaliera Universitaria Senese
ClinicalTrials.gov Identifier:
NCT01655888
First received: July 31, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)